Literature DB >> 32269029

Mineralocorticoid Receptor Antagonists in ESKD.

Adhish Agarwal1, Alfred K Cheung2.   

Abstract

Entities:  

Keywords:  Humans; Kidney Failure, Chronic; aldosterone; cardiovascular diseases; chronic kidney failure; chronic renal insufficiency; diabetes mellitus; heart failure; hospitalization; hyperaldosteronism; mineralocorticoid receptor antagonists; mineralocorticoids; renal dialysis; risk factors

Year:  2020        PMID： 32269029      PMCID： PMC7341785          DOI： 10.2215/CJN.13221019

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

2.  Aldosterone stimulates K secretion across mammalian colon independent of Na absorption.

Authors:  G Rechkemmer; D R Halm
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.

Authors:  Fabian Hammer; Uwe Malzahn; Julian Donhauser; Christoph Betz; Markus P Schneider; Clemens Grupp; Nils Pollak; Stefan Störk; Christoph Wanner; Vera Krane
Journal:  Kidney Int       Date:  2019-01-31       Impact factor: 10.612

4.  Long-term effects of spironolactone in peritoneal dialysis patients.

Authors:  Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Hirofumi Tamai; Takeyuki Hiramatsu; Hiroshige Ohashi; Isao Ito; Hirotake Kasuga; Masanobu Horie; Shoichi Maruyama; Yukio Yuzawa; Tatsuaki Matsubara; Seiichi Matsuo
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

5.  Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Authors:  David M Charytan; Jonathan Himmelfarb; T Alp Ikizler; Dominic S Raj; Jesse Y Hsu; J Richard Landis; Amanda H Anderson; Adriana M Hung; Rajnish Mehrotra; Shailendra Sharma; Daniel E Weiner; Mark Williams; Marcelo DiCarli; Hicham Skali; Paul L Kimmel; Alan S Kliger; Laura M Dember
Journal:  Kidney Int       Date:  2018-11-23       Impact factor: 10.612

6.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

7.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).

Authors:  Orly Vardeny; Dong Hong Wu; Akshay Desai; Patrick Rossignol; Faiez Zannad; Bertram Pitt; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

8.  Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Authors:  Yoshihiro Matsumoto; Yasuo Mori; Shinji Kageyama; Kazuo Arihara; Toshikazu Sugiyama; Hiromichi Ohmura; Toru Yakushigawa; Hatsumi Sugiyama; Yasushi Shimada; Youichi Nojima; Nobuo Shio
Journal:  J Am Coll Cardiol       Date:  2013-10-30       Impact factor: 24.094

9.  Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.

Authors:  ChongTing Lin; Qing Zhang; HuiFang Zhang; AiXia Lin
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-30       Impact factor: 3.738

10.  Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.

Authors:  Christiane Drechsler; Eberhard Ritz; Andreas Tomaschitz; Stefan Pilz; Stephan Schönfeld; Katja Blouin; Martin Bidlingmaier; Fabian Hammer; Vera Krane; Winfried März; Bruno Allolio; Martin Fassnacht; Christoph Wanner
Journal:  Eur Heart J       Date:  2012-12-04       Impact factor: 29.983
  10 in total
  1 in total

Review 1.  Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Authors:  Nina Vodošek Hojs; Sebastjan Bevc; Robert Ekart; Nejc Piko; Tadej Petreski; Radovan Hojs
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.